Inclusion Criteria:  Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2. Age ≥18 years at the time of signing the informed consent. Known neoplastic disease prior to the initiation of chemotherapy with a high dose of anthracyclines (doxorubicin ≥ 240 mg / m2 b.w. or epirubicin ≥ 540 mg / m2 b.w.) No history of heart failure (left ventricular ejection fraction ≥ 50% as assessed by echocardiography). Missing history of: coronary artery disease, stroke and lower limb atherosclerosis Presence of at least two of the above-mentioned risk factors for the development of atherosclerosis (hypertension, diabetes, dyslipidemia, obesity (BMI≥30), smoking)  Exclusion Criteria:  History of heart failure Left ventricle systolic dysfunction with LVEF <50% Significant valve defect Previous chemotherapy or radiation to the chest Presence of any disease with a life expectancy <1 year in the opinion of the investigator. Drug or alcohol abuse Lack of possibility or contraindications for coronary tomography before starting chemotherapy